ADAGIO MEDICAL HOLDINGS INC - FULCRUM-VT TRIAL DEMONSTRATES 98% NON-INDUCIBILITY OF TARGETED VT AT PROCEDURE'S CONCLUSION
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 26 2026
0mins
Should l Buy ADGM?
Source: moomoo
- Trial Results: A recent trial by AGA Medical Holdings demonstrated a 98% non-inducibility of targeted VT at the end of the procedure.
- Significance: These findings suggest a high efficacy of the treatment method being tested, indicating potential advancements in medical procedures related to VT.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADGM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADGM
Wall Street analysts forecast ADGM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.953
Low
4.00
Averages
4.00
High
4.00
Current: 0.953
Low
4.00
Averages
4.00
High
4.00
About ADGM
Adagio Medical Holdings, Inc. is a medical device company. The Company is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FULCRUM-VT Trial Demonstrates Effectiveness of Cardiac Ablation Technology
- Clinical Trial Results: The FULCRUM-VT trial demonstrated that 84% of patients experienced no ICD shocks within six months, and 59% had no VT recurrence, indicating the technology's effectiveness in cardiac patients and potentially changing treatment standards.
- Safety Analysis: The trial reported a low major adverse event rate of only 2.4%, showcasing a favorable safety profile, with just 1.9% of patients readmitted for VT-related issues within six months, thereby reducing medical risks for patients.
- Technological Innovation: Adagio's vCLAS ablation system showed equivalent effectiveness in both ischemic and non-ischemic cardiomyopathy patients, marking the first evidence of broad applicability across different pathological backgrounds, which may drive wider clinical adoption.
- Market Potential: With approximately 300,000 sudden cardiac deaths due to ventricular arrhythmias annually in the U.S., the positive results from FULCRUM-VT provide a strong market entry opportunity for Adagio's ULTA technology, expected to attract more investment and improve patient outcomes.
See More
ADAGIO MEDICAL HOLDINGS INC - FULCRUM-VT TRIAL DEMONSTRATES 98% NON-INDUCIBILITY OF TARGETED VT AT PROCEDURE'S CONCLUSION
- Trial Results: A recent trial by AGA Medical Holdings demonstrated a 98% non-inducibility of targeted VT at the end of the procedure.
- Significance: These findings suggest a high efficacy of the treatment method being tested, indicating potential advancements in medical procedures related to VT.
See More
Adagio Medical Receives IDE Approval for vCLAS System Expansion
- Clinical Trial Expansion: Adagio Medical has received Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT trial, evaluating the next-generation vCLAS Ultra-Low Temperature Ablation System for treating sustained monomorphic ventricular tachycardia, marking a significant advancement in cardiac rhythm disorder treatment.
- Technological Innovation: The vCLAS system aims to create effective lesions more efficiently by delivering ultra-cold temperatures around -170 °C, addressing the limitations of current ablation tools that struggle to achieve deep and durable lesions, thereby enhancing treatment outcomes.
- Clinical Study Design: The expanded clinical sub-study will enroll up to 55 patients across multiple centers focusing on scar-mediated SMVT, intending to generate additional safety and effectiveness data to support the pivotal phase of the FULCRUM-VT trial.
- Market Potential: Adagio executives stated that the IDE approval represents an important milestone in advancing technology that could broaden access to VT ablation, with the vCLAS Ultra catheter having the potential to become a scalable endocardial-only solution capable of treating a wide range of VT substrates.
See More
Adagio Receives FDA Approval to Expand Clinical Trial
- Clinical Trial Expansion: Adagio Medical has received FDA approval to expand its FULCRUM-VT trial, evaluating the safety and efficacy of the next-generation vCLAS Ultra-Low Temperature Ablation System for treating Sustained Monomorphic Ventricular Tachycardia (SMVT), marking a significant advancement in cardiac treatment technology.
- Technological Innovation: The new vCLASUltracatheter achieves ablation temperatures of approximately -170°C, significantly enhancing ablation efficiency and reducing ablation time by over 50%, which is expected to improve clinical workflow and patient treatment experience.
- Market Potential: The IDE expansion approval enables Adagio to conduct a prospective, single-arm, multi-center study involving 55 patients, further validating the effectiveness of its technology and aiding the company's penetration and product promotion in the cardiac electrophysiology market.
- Strategic Goals: Adagio aims to translate its ULTA technology into a widely applicable solution, targeting the treatment of a large underserved population suffering from ventricular tachycardia, thereby enhancing the company's leadership position in the cardiac medical device market.
See More
Adagio Medical Q4 Earnings Beat Expectations
- Earnings Performance: Adagio Medical Holdings reported a Q4 GAAP EPS of -$0.21, beating market expectations by $0.10, indicating an improving trend in financial performance.
- Significant Cost Reduction: The cost of revenue for Q4 2025 was $58,000, a substantial decrease from $1.5 million in Q4 2024, demonstrating the company's effective cost control measures.
- R&D Spending Decrease: Research and development expenses for Q4 2025 were $2.2 million, down from $3.4 million in Q4 2024, reflecting optimization in resource allocation that may impact future innovation capabilities.
- Net Loss Reduction: The net loss for Q4 2025 was $3.3 million, significantly reduced from $57.4 million in Q4 2024, showcasing positive progress in the company's financial health.
See More
Adagio Completes 13 Ventricular Ablation Procedures Using ULTA Technology
- Technological Breakthrough: Adagio Medical has successfully completed 13 ventricular ablation procedures using its proprietary Ultra-Low Temperature Ablation (ULTA) technology at leading institutions, marking a significant advancement in treating patients with no satisfactory treatment options, showcasing the technology's potential in managing refractory arrhythmias.
- Patient Benefits: These procedures targeted patients who had previously failed conventional and experimental ablation therapies, indicating the effectiveness of ULTA technology in handling complex cases, which may provide new treatment options for cardiac patients and enhance the company's competitiveness in the cardiac ablation market.
- Clinical Need: Under the FDA's Expanded Access authorization, ULTA technology offers treatment opportunities for patients facing serious or life-threatening diseases, emphasizing its importance in managing ventricular arrhythmias and potentially transforming existing treatment paradigms.
- Future Outlook: Adagio plans to apply for FDA approval of its vCLAS™ Cryoablation System by the end of 2026, which is expected to provide broader industry indications for the treatment of ventricular arrhythmias, further solidifying its market position.
See More
FULCRUM-VT Trial Demonstrates Effectiveness of Cardiac Ablation Technology
- Clinical Trial Results: The FULCRUM-VT trial demonstrated that 84% of patients experienced no ICD shocks within six months, and 59% had no VT recurrence, indicating the technology's effectiveness in cardiac patients and potentially changing treatment standards.
- Safety Analysis: The trial reported a low major adverse event rate of only 2.4%, showcasing a favorable safety profile, with just 1.9% of patients readmitted for VT-related issues within six months, thereby reducing medical risks for patients.
- Technological Innovation: Adagio's vCLAS ablation system showed equivalent effectiveness in both ischemic and non-ischemic cardiomyopathy patients, marking the first evidence of broad applicability across different pathological backgrounds, which may drive wider clinical adoption.
- Market Potential: With approximately 300,000 sudden cardiac deaths due to ventricular arrhythmias annually in the U.S., the positive results from FULCRUM-VT provide a strong market entry opportunity for Adagio's ULTA technology, expected to attract more investment and improve patient outcomes.
See More
ADAGIO MEDICAL HOLDINGS INC - FULCRUM-VT TRIAL DEMONSTRATES 98% NON-INDUCIBILITY OF TARGETED VT AT PROCEDURE'S CONCLUSION
- Trial Results: A recent trial by AGA Medical Holdings demonstrated a 98% non-inducibility of targeted VT at the end of the procedure.
- Significance: These findings suggest a high efficacy of the treatment method being tested, indicating potential advancements in medical procedures related to VT.
See More
Adagio Medical Receives IDE Approval for vCLAS System Expansion
- Clinical Trial Expansion: Adagio Medical has received Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT trial, evaluating the next-generation vCLAS Ultra-Low Temperature Ablation System for treating sustained monomorphic ventricular tachycardia, marking a significant advancement in cardiac rhythm disorder treatment.
- Technological Innovation: The vCLAS system aims to create effective lesions more efficiently by delivering ultra-cold temperatures around -170 °C, addressing the limitations of current ablation tools that struggle to achieve deep and durable lesions, thereby enhancing treatment outcomes.
- Clinical Study Design: The expanded clinical sub-study will enroll up to 55 patients across multiple centers focusing on scar-mediated SMVT, intending to generate additional safety and effectiveness data to support the pivotal phase of the FULCRUM-VT trial.
- Market Potential: Adagio executives stated that the IDE approval represents an important milestone in advancing technology that could broaden access to VT ablation, with the vCLAS Ultra catheter having the potential to become a scalable endocardial-only solution capable of treating a wide range of VT substrates.
See More
Adagio Receives FDA Approval to Expand Clinical Trial
- Clinical Trial Expansion: Adagio Medical has received FDA approval to expand its FULCRUM-VT trial, evaluating the safety and efficacy of the next-generation vCLAS Ultra-Low Temperature Ablation System for treating Sustained Monomorphic Ventricular Tachycardia (SMVT), marking a significant advancement in cardiac treatment technology.
- Technological Innovation: The new vCLASUltracatheter achieves ablation temperatures of approximately -170°C, significantly enhancing ablation efficiency and reducing ablation time by over 50%, which is expected to improve clinical workflow and patient treatment experience.
- Market Potential: The IDE expansion approval enables Adagio to conduct a prospective, single-arm, multi-center study involving 55 patients, further validating the effectiveness of its technology and aiding the company's penetration and product promotion in the cardiac electrophysiology market.
- Strategic Goals: Adagio aims to translate its ULTA technology into a widely applicable solution, targeting the treatment of a large underserved population suffering from ventricular tachycardia, thereby enhancing the company's leadership position in the cardiac medical device market.
See More
Adagio Medical Q4 Earnings Beat Expectations
- Earnings Performance: Adagio Medical Holdings reported a Q4 GAAP EPS of -$0.21, beating market expectations by $0.10, indicating an improving trend in financial performance.
- Significant Cost Reduction: The cost of revenue for Q4 2025 was $58,000, a substantial decrease from $1.5 million in Q4 2024, demonstrating the company's effective cost control measures.
- R&D Spending Decrease: Research and development expenses for Q4 2025 were $2.2 million, down from $3.4 million in Q4 2024, reflecting optimization in resource allocation that may impact future innovation capabilities.
- Net Loss Reduction: The net loss for Q4 2025 was $3.3 million, significantly reduced from $57.4 million in Q4 2024, showcasing positive progress in the company's financial health.
See More
Adagio Completes 13 Ventricular Ablation Procedures Using ULTA Technology
- Technological Breakthrough: Adagio Medical has successfully completed 13 ventricular ablation procedures using its proprietary Ultra-Low Temperature Ablation (ULTA) technology at leading institutions, marking a significant advancement in treating patients with no satisfactory treatment options, showcasing the technology's potential in managing refractory arrhythmias.
- Patient Benefits: These procedures targeted patients who had previously failed conventional and experimental ablation therapies, indicating the effectiveness of ULTA technology in handling complex cases, which may provide new treatment options for cardiac patients and enhance the company's competitiveness in the cardiac ablation market.
- Clinical Need: Under the FDA's Expanded Access authorization, ULTA technology offers treatment opportunities for patients facing serious or life-threatening diseases, emphasizing its importance in managing ventricular arrhythmias and potentially transforming existing treatment paradigms.
- Future Outlook: Adagio plans to apply for FDA approval of its vCLAS™ Cryoablation System by the end of 2026, which is expected to provide broader industry indications for the treatment of ventricular arrhythmias, further solidifying its market position.
See More
